Our innovative proprietary formulation drug delivery technology platform, Arestat®, enables superior products with enhanced properties that improve patient care and outcomes.

Arestat® results in improved product formats with enhanced properties ranging from greater safety and convenience through to superior therapeutic profiles which can improve patient care and health outcomes.

Arestat® can be applied to high-value biologics, including biosimilars, novel biologics, peptides and vaccines, as well as future potential applications such as oral delivery, mRNA and cell and gene therapies

Development of formulations with our Arestat® technology follow four key steps:

Infographic showing development of the formulations with enhanced properties using the Arestat® technology's four key steps

  •  

    Examples of Arestat®-enhanced, superior product profiles include:

    Liquid products with superior stability

    → Enables use outside the cold chain, improved shelf-life

    Lyophilised powder to liquid switch

    → Convenient liquid product to replace lyophilised compositions requiring complex reconstitution

    High concentration products for subcutaneous administration

    → Low viscosity and low rate of aggregation

    Ready-to-use (RTU) and ready-to-administer (RTA) formats

    →  Stable liquid concentrates for intravenous (IV) administration or pre-mixed IV bags

    Control of absorption from subcutaneous injection site

    → Improved pharmacokinetic/ pharmacodynamic (PK/PD) profiles

    Arestat® is protected by a broad and robust intellectual property